Cognoptix
Curated by SignalDeveloper of non-invasive eye scanning tests for early detection of Alzheimer's Disease
Overview
Cognoptix is a developer of non-invasive eye scanning tests for early detection of Alzheimer's Disease. The company is developing technologies to enable non-invasive quantitative measurements of amyloid aggregates in the eye, to examine and measure deposits in specific areas of the lens as a means of early detection of Alzheimer’s disease. Their SAPPHIRE eye test uses Fluorescent Ligand Scanning (FLS) is a technique in which a compound composed of beta amyloid-specific small molecules is dropped into a patient’s eye, which is scanned by the SAPPHIRE instrument.
Key facts
- Founded
- 2001
- Headquarters
- Acton, United States
- Stage
- Sign up to view
- Industry
- Life Sciences Technology
Business model
- 3 products and services
- Sign up to view
Contact
- Primary office
- Sign up to view